Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative treatments for serious diseases, particularly in the oncology space. The company is advancing its proprietary drug candidates through comprehensive clinical trials, addressing significant unmet medical needs to enhance patient outcomes. With a focus on building a robust pipeline of transformative therapeutic solutions, Actuate is positioned to drive strategic growth and deliver substantial value to its investors, solidifying its competitive edge within the biotechnology industry. Show more

1751 RIVER RUN, FORT WORTH, TX, UNITED STATES, 76107, Fort Worth, TX, 76107, USA

https://actuatetherapeutics.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

29.54M

52 Wk Range

$0.90 - $9.22

Previous Close

$1.06

Open

$1.06

Volume

938,987

Day Range

$1.01 - $1.34

Enterprise Value

31.76M

Cash

4.426M

Avg Qtr Burn

-4.405M

Insider Ownership

15.41%

Institutional Own.

56.32%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Elraglusib Details Advanced Salivary Gland Carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elraglusib + Folfirinox + Losartan (ELRA) (GSK-3β Inhibitor) Details First-Line Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elraglusib + gemcitabine/nab-paclitaxel (GnP) Details 1L metastatic pancreatic ductal adenocarcinoma (mPDAC)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elraglusib (ELRA) (GSK-3β Inhibitor) Details Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elraglusib (GSK-3β Inhibitor) Details Relapsed/Refractory Neuroblastoma	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elraglusib (GSK-3β Inhibitor) Details Relapsed/Refractory Ewing Sarcoma	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Oral Elraglusib (GSK-3β Inhibitor) Details Advanced Cancers Including Refractory Metastatic Melanoma	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.